Skip to main content

Bioeffects of CdTe Quantum Dots on Human Umbilical Vein Endothelial Cells

Buy Article:

$107.14 + tax (Refund Policy)

Quantum dots (QDs) hold great potential for applications in nanomedicine, however, their health effects are largely unknown. In the present study, the cytotoxicity and genotoxicity of CdTe QDs were examined in human umbilical vein endothelial cells (HUVECs). The QDs exhibited a dose-dependent inhibitory effect on cell growth. It was shown that after a 12 h treatment QDs at 1, 10, and 50 g·ml−1 induced formation of H2AX foci, indicative of DNA damage, in a dose-dependent manner. Moreover, QD treatment clearly induced the generation of reactive oxygen species (ROS). Pre-treatment with N-acetyl-cysteine (NAC), a ROS scavenger, could inhibit the induction of ROS by QDs, as well as the formation of H2AX foci. Taken together, our data indicate that CdTe QDs have cytotoxic and genotoxic effects on HUVECs, and that ROS generation may be involved in QD induced DNA damage.

Keywords: DNA DAMAGE; GAMMA H2AX; QUANTUM DOTS; REACTIVE OXYGEN SPECIES

Document Type: Research Article

Publication date: 01 December 2010

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content